

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 24, 2019

**REPRO MED SYSTEMS, INC.**

(Exact name of registrant as specified in its charter)

**New York**  
(State or other jurisdiction  
of incorporation)

**0-12305**  
(Commission  
File Number)

**13-3044880**  
(IRS Employer  
Identification No.)

**24 Carpenter Road, Chester, New York**  
(Address of principal executive offices)

**10918**  
(Zip Code)

Registrant's telephone number, including area code **(845) 469-2042**

not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading symbol(s)</u>	<u>Name of each exchange on which registered</u>
common stock, \$0.01 par value	REPR	OTCQX

---

**ITEM 8.01 OTHER EVENTS.**

As previously reported in the Company's reports filed under the Securities Exchange Act of 1934, as amended, on June 25, 2015, EMED Technologies Corporation ("EMED") filed a case in the United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement on one of its patents by the Company's needle sets, and seeking unspecified monetary damages ("ED Texas '476 matter"). This case is one of several pending between RMS Medical and EMED.

The Company is filing this Current Report on Form 8-K to report that, on June 24, 2019, the Texas Court Magistrate Judge issued a Report and Recommendation decision with respect to the ED Texas '476 matter finding no infringement, literally or under the doctrine of equivalents, by the Company's accused products. On June 26, 2019, EMED filed objections to the decision. Procedurally, all deadlines and pending motions are now suspended until the District Judge reviews the decision together with EMED's objection and the briefing on the objections, and makes a final determination.

The Company believes it will prevail on the merits and the District Judge will uphold the decision of the Magistrate Judge, although an adverse outcome in this matter could materially and adversely affect the Company's business, financial condition, results of operations and cash flows.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPRO MED SYSTEMS, INC.  
(Registrant)

Date: June 27, 2019

By: /s/ Karen Fisher  
Karen Fisher  
Chief Financial Officer